MAIA Biotechnology, Inc. (MAIA) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
19.33
+12% vs avg
5yr avg: 17.27
30Y Low3.8·High32.5
ROE
↓
-745.2%
↑-32% vs avg
5yr avg: -565.0%
30Y Low-490%·High-178%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
MAIA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
MAIA Biotechnology, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $55M | $49M | $44M | $16M | $33M | — | — | — |
| Enterprise Value | $-8602747801 | $-8608895050 | $34M | $8M | $22M | — | — | — |
| P/E Ratio → | -2.04 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — |
| P/B Ratio | 19.33 | 20.68 | 12.09 | 32.49 | 3.83 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
MAIA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
MAIA Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -745.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -745.2% | -745.2% | -1131.0% | -440.1% | -178.3% | -330.6% | — | -490.1% |
| ROA | -225.5% | -225.5% | -262.4% | -201.9% | -135.1% | -207.1% | -535.0% | -374.3% |
| ROIC | — | — | — | — | — | — | — | — |
| ROCE | -476.2% | -476.2% | -378.7% | -354.6% | -180.4% | -189.1% | -3380.3% | -508.9% |
MAIA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $8.7B exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | 0.03 |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -3644.16 | -2.64 | -14.97 | -1.29 | -1.15 | — | -1.26 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -407975.42 | — | -2262.42 | -14.20 | -221.12 | — |
Net cash position: cash ($8.7B) exceeds total debt ($0)
MAIA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.66x means MAIA Biotechnology, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has improved from 1.53x to 1.66x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.66 | 1.66 | 2.65 | 1.53 | 3.61 | 4.97 | 0.44 | 4.63 |
| Quick Ratio | 1.66 | 1.66 | 2.65 | 1.53 | 3.61 | 4.97 | 0.44 | 4.63 |
| Cash Ratio | 1483.45 | 1483.45 | 2.51 | 1.45 | 3.35 | 4.93 | 0.39 | 4.56 |
| Asset Turnover | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
MAIA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
MAIA Biotechnology, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $32M | $22M | $13M | $9M | $11M | $11M | $11M |
Peer Comparison
Compare MAIA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 MAIAYou | $55M | -2.0 | — | — | — | — | -745.2% | — | — |
 TELO | $42M | -3.7 | — | — | — | — | -317.6% | — | — |
 IMVT | $6B | -11.2 | — | — | — | — | -64.8% | — | — |
 AGEN | $134M | -947.1 | — | — | 29.6% | -18.0% | — | — | — |
 CYCN | $13M | -2.8 | — | — | 100.0% | -239.8% | -39.3% | -65.1% | — |
 TPVG | $218M | 4.4 | 8.8 | — | 83.5% | 77.9% | 14.1% | 7.2% | 6.2 |
 ACAD | $4B | 9.4 | 25.5 | 34.9 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 NKTR | $1B | -6.1 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 HALO | $8B | 27.3 | 11.4 | 12.8 | 78.1% | 58.4% | 153.6% | 32.1% | 2.4 |
 FATE | $255M | -1.9 | — | — | -94.1% | -2222.4% | -51.8% | -36.5% | — |
 RCUS | $2B | -7.3 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
| Healthcare Median | — | 22.2 | 13.9 | 18.2 | 64.0% | -4.2% | -32.4% | -11.1% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
What if you invested $1,000 in MAIA 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in MAIA be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs MAIA Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationMAIA vs TELO — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Telomir Pharmaceuticals, Inc. Common Stock.
Compare NowMAIA — Frequently Asked Questions
Quick answers to the most common questions about buying MAIA stock.
What is MAIA Biotechnology, Inc.'s P/E ratio?
MAIA Biotechnology, Inc.'s current P/E ratio is -2.0x. This places it at the 50th percentile of its historical range.
What is MAIA Biotechnology, Inc.'s ROE?
MAIA Biotechnology, Inc.'s return on equity (ROE) is -745.2%. The historical average is -359.8%.
Is MAIA stock overvalued?
Based on historical data, MAIA Biotechnology, Inc. is trading at a P/E of -2.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.